BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26753639)

  • 21. Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA.
    Zekri A; Mesbahi Y; Ghanizadeh-Vesali S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Anticancer Drugs; 2017 Sep; 28(8):841-851. PubMed ID: 28639950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
    Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
    Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
    [No Abstract]   [Full Text] [Related]  

  • 23. Janus face-like effects of Aurora B inhibition: antitumoral mode of action versus induction of aneuploid progeny.
    Wiedemuth R; Klink B; Fujiwara M; Schröck E; Tatsuka M; Schackert G; Temme A
    Carcinogenesis; 2016 Oct; 37(10):993-1003. PubMed ID: 27515963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.
    Oke A; Pearce D; Wilkinson RW; Crafter C; Odedra R; Cavenagh J; Fitzgibbon J; Lister AT; Joel S; Bonnet D
    Cancer Res; 2009 May; 69(10):4150-8. PubMed ID: 19366807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT.
    Baldini E; Arlot-Bonnemains Y; Sorrenti S; Mian C; Pelizzo MR; De Antoni E; Palermo S; Morrone S; Barollo S; Nesca A; Moretti CG; D'Armiento M; Ulisse S
    BMC Cancer; 2011 Sep; 11():411. PubMed ID: 21943074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
    Tao Y; Zhang P; Girdler F; Frascogna V; Castedo M; Bourhis J; Kroemer G; Deutsch E
    Oncogene; 2008 May; 27(23):3244-55. PubMed ID: 18084327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apigenin induces autophagic cell death in human papillary thyroid carcinoma BCPAP cells.
    Zhang L; Cheng X; Gao Y; Zheng J; Xu Q; Sun Y; Guan H; Yu H; Sun Z
    Food Funct; 2015 Nov; 6(11):3464-72. PubMed ID: 26292725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Potential Contribution of microRNAs in Anti-cancer Effects of Aurora Kinase Inhibitor (AZD1152-HQPA).
    Zekri A; Mesbahi Y; Boustanipour E; Sadr Z; Ghaffari SH
    J Mol Neurosci; 2018 Aug; 65(4):444-455. PubMed ID: 30051358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
    Muscal JA; Scorsone KA; Zhang L; Ecsedy JA; Berg SL
    Invest New Drugs; 2013 Feb; 31(1):39-45. PubMed ID: 22669335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aurora kinase B/C inhibition impairs malignant glioma growth in vivo.
    Diaz RJ; Golbourn B; Shekarforoush M; Smith CA; Rutka JT
    J Neurooncol; 2012 Jul; 108(3):349-60. PubMed ID: 22382783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aurora kinases: new molecular targets in thyroid cancer therapy.
    Baldini E; Sorrenti S; D'Armiento E; Prinzi N; Guaitoli E; Favoriti P; Gnessi L; Moretti C; Bianchini M; Alessandrini S; Catania A; De Antoni E; Ulisse S
    Clin Ter; 2012 Nov; 163(6):e457-62. PubMed ID: 23306762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines.
    Baldini E; Sorrenti S; D'Armiento E; Guaitoli E; Morrone S; D'Andrea V; Gnessi L; Moretti C; Antonelli A; Catania A; De Antoni E; Ulisse S
    Clin Ter; 2012; 163(5):e307-13. PubMed ID: 23099978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5'-AMP-Activated Protein Kinase Regulates Papillary (TPC-1 and BCPAP) Thyroid Cancer Cell Survival, Migration, Invasion, and Epithelial-to-Mesenchymal Transition.
    Cazarin JM; Coelho RG; Hecht F; Andrade BM; Carvalho DP
    Thyroid; 2016 Jul; 26(7):933-42. PubMed ID: 27121619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.
    Tao Y; Leteur C; Calderaro J; Girdler F; Zhang P; Frascogna V; Varna M; Opolon P; Castedo M; Bourhis J; Kroemer G; Deutsch E
    Cell Cycle; 2009 Oct; 8(19):3172-81. PubMed ID: 19755861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Treatment of Medullary and Papillary Human Thyroid Cancer: Biological Effects of Hyaluronic Acid Hydrogel Loaded With Quercetin Alone or in Combination to an Inhibitor of Aurora Kinase.
    Quagliariello V; Armenia E; Aurilio C; Rosso F; Clemente O; de Sena G; Barbarisi M; Barbarisi A
    J Cell Physiol; 2016 Aug; 231(8):1784-95. PubMed ID: 26660542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.
    Qi W; Spier C; Liu X; Agarwal A; Cooke LS; Persky DO; Chen D; Miller TP; Mahadevan D
    Leuk Res; 2013 Apr; 37(4):434-9. PubMed ID: 23153524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
    Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
    BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
    Nair JS; de Stanchina E; Schwartz GK
    Clin Cancer Res; 2009 Mar; 15(6):2022-30. PubMed ID: 19276280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
    Li X; Li Z; Song Y; Liu W; Liu Z
    Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.